Industry leaders and policy experts have said President Trump’s executive order on Most Favored Pricing is flawed and ignores the basic economics of the global drug marketplace.

The House Energy and Commerce Committee has scheduled a public markup hearing for the Republican bill for tomorrow at 2 p.m.

In a press conference, President Donald J. Trump announced that he would sign an executive order that ties drug pricing to ...

Healthcare providers are exploring ways to reduce patient travel through a growing trend of expanding sites of administration ...

A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...

Specialty drugs are increasingly entering general medicine. Experts at Asembia’s AXS Summit say the trend will put a premium ...

In a conversation with Managed Healthcare Executive, 10XBeta CEO Marcel Botha warned that proposed Medicaid cuts, combined ...

It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are ...

Kaminski and his colleagues were pioneers in applying high-throughput, genome-scale transcript profiling to advanced lung ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...

Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started ...